JP5406040B2 - 医薬使用のためのリパーゼ変異体 - Google Patents

医薬使用のためのリパーゼ変異体 Download PDF

Info

Publication number
JP5406040B2
JP5406040B2 JP2009543078A JP2009543078A JP5406040B2 JP 5406040 B2 JP5406040 B2 JP 5406040B2 JP 2009543078 A JP2009543078 A JP 2009543078A JP 2009543078 A JP2009543078 A JP 2009543078A JP 5406040 B2 JP5406040 B2 JP 5406040B2
Authority
JP
Japan
Prior art keywords
lipase
seq
enzyme
amino acids
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009543078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512795A (ja
JP2010512795A5 (enExample
Inventor
スベンセン，アラン
スクヨエット，ミシェル
ヤバー，デビー
レーマン ヒュリング クリステンセン，ラーズ
エスキルセン ラーセン，シグネ
ルンディン，ニーナ
ランサ，マイケル
コリン グレゴリー，ピーター
Original Assignee
ノボザイムス アクティーゼルスカブ
ノボザイムス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボザイムス アクティーゼルスカブ, ノボザイムス，インコーポレイティド filed Critical ノボザイムス アクティーゼルスカブ
Publication of JP2010512795A publication Critical patent/JP2010512795A/ja
Publication of JP2010512795A5 publication Critical patent/JP2010512795A5/ja
Application granted granted Critical
Publication of JP5406040B2 publication Critical patent/JP5406040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009543078A 2006-12-21 2007-12-12 医薬使用のためのリパーゼ変異体 Active JP5406040B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21
US60/871,196 2006-12-21
PCT/US2007/087168 WO2008079685A2 (en) 2006-12-21 2007-12-12 Lipase variants for pharmaceutical use

Publications (3)

Publication Number Publication Date
JP2010512795A JP2010512795A (ja) 2010-04-30
JP2010512795A5 JP2010512795A5 (enExample) 2011-02-03
JP5406040B2 true JP5406040B2 (ja) 2014-02-05

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543078A Active JP5406040B2 (ja) 2006-12-21 2007-12-12 医薬使用のためのリパーゼ変異体

Country Status (16)

Country Link
US (3) US8273348B2 (enExample)
EP (6) EP2455460A3 (enExample)
JP (1) JP5406040B2 (enExample)
KR (1) KR20090101930A (enExample)
CN (2) CN105112386A (enExample)
AR (1) AR064494A1 (enExample)
AU (1) AU2007337150A1 (enExample)
BR (1) BRPI0721103A2 (enExample)
CA (3) CA3081308C (enExample)
IL (1) IL198893A0 (enExample)
MX (1) MX2009006597A (enExample)
NO (1) NO20092729L (enExample)
RU (1) RU2009128067A (enExample)
TW (1) TW200829698A (enExample)
WO (1) WO2008079685A2 (enExample)
ZA (1) ZA200903598B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5032300B2 (ja) 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
EP1913138B1 (en) 2005-07-29 2016-08-24 Abbott Laboratories GmbH Processes for the manufacture of pancreatin powder with low virus content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
JP5406040B2 (ja) * 2006-12-21 2014-02-05 ノボザイムス アクティーゼルスカブ 医薬使用のためのリパーゼ変異体
CA2716692A1 (en) 2008-02-29 2009-09-03 Dsm Ip Assets B.V. Lipases with high specificity towards short chain fatty acids and uses thereof
AR070498A1 (es) * 2008-02-29 2010-04-07 Procter & Gamble Composicion detergente que comprende lipasa
EP2250258B1 (en) 2008-02-29 2017-01-04 Novozymes A/S Lipolytic enzyme variant with improved stability and polynucleotides encoding same
EP4159833A3 (en) 2009-12-09 2023-07-26 The Procter & Gamble Company Fabric and home care products
DK2734633T3 (da) 2011-07-22 2019-06-11 Novozymes North America Inc Fremgangsmåder til forbehandling af celluloseholdigt materiale og forbedring af hydrolyse deraf
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
CN110777016A (zh) * 2011-12-29 2020-02-11 诺维信公司 具有脂肪酶变体的洗涤剂组合物
MX391773B (es) * 2012-02-03 2025-03-21 Novozymes As Variantes de lipasa y polinucleótidos que las codifican.
CN104204198B (zh) * 2012-04-02 2018-09-25 诺维信公司 脂肪酶变体以及编码其的多核苷酸
AU2013328953A1 (en) * 2012-10-12 2015-03-26 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
AR096270A1 (es) 2013-05-14 2015-12-16 Novozymes As Composiciones detergentes
MX371497B (es) * 2013-07-19 2020-01-31 Danisco Us Inc Composiciones y metodos que comprenden una variante de enzima lipolitica.
CN107075489A (zh) * 2014-11-20 2017-08-18 诺维信公司 脂环酸芽孢杆菌变体以及编码它们的多核苷酸
WO2016087401A1 (en) * 2014-12-05 2016-06-09 Novozymes A/S Lipase variants and polynucleotides encoding same
MX382218B (es) 2014-12-09 2025-03-13 Novozymes As Variantes de lipasa y polinucleotidos que las codifican.
US20180355404A1 (en) 2015-04-07 2018-12-13 Novozymes A/S Methods for selecting enzymes having lipase activity
EP3317407B1 (en) * 2015-07-01 2021-05-19 Novozymes A/S Methods of reducing odor
WO2017005640A1 (en) * 2015-07-03 2017-01-12 Novozymes A/S Detergent compositions with improved stability in the presence of sulfites
CN109790525A (zh) 2016-07-18 2019-05-21 诺维信公司 脂肪酶变体、编码其的多核苷酸及其用途
JP7081767B2 (ja) * 2017-01-30 2022-06-07 学校法人日本医科大学 アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体
MX2020002964A (es) 2017-09-27 2020-07-22 Novozymes As Variantes de lipasa y composiciones de microcapsula que comprenden las variantes de lipasa.
US11286443B2 (en) * 2017-09-27 2022-03-29 The Procter & Gamble Company Detergent compositions comprising lipases
WO2019154955A1 (en) * 2018-02-08 2019-08-15 Novozymes A/S Lipase variants and compositions thereof
US12269847B2 (en) * 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
JP7741827B2 (ja) * 2020-06-24 2025-09-18 シリアン アクチェンゲゼルシャフト 新規リパーゼ酵素
JP2023547450A (ja) * 2020-10-29 2023-11-10 ノボザイムス アクティーゼルスカブ リパーゼ変異体及びそのようなリパーゼ変異体を含む組成物
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
EP4525615A2 (en) 2022-05-14 2025-03-26 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4544015A2 (en) * 2022-06-24 2025-04-30 Novozymes A/S Lipase variants and compositions comprising such lipase variants

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
DK0548228T3 (da) * 1990-09-13 1999-05-10 Novo Nordisk As Lipasevarianter
DK46693D0 (enExample) * 1993-04-23 1993-04-23 Novo Nordisk As
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
ATE170630T1 (de) 1990-12-05 1998-09-15 Novo Nordisk As Proteine mit geänderten epitopen und verfahren zur deren herstellung
FI934812L (fi) 1991-05-01 1993-10-29 Novo Nordisk As Stabiliserade entzymer
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
AU7807394A (en) 1993-10-04 1995-05-01 Novo Nordisk A/S An enzyme preparation comprising a modified enzyme
KR970701264A (ko) 1994-02-22 1997-03-17 안네 제케르 지질분해효소의 변이체 제조방법(a method of preparing a viriant of a lipolytic enzyme)
EP0793726A1 (en) 1994-11-24 1997-09-10 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
CA2206852A1 (en) 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
DE69617641T3 (de) 1995-01-26 2009-10-22 Novozymes A/S Xylanase beinhaltende futterzusätze für tiere
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
DE69633825T2 (de) 1995-07-14 2005-11-10 Novozymes A/S Modifiziertes enzym mit lipolytischer aktivität
EP0851913B1 (en) 1995-08-11 2004-05-19 Novozymes A/S Novel lipolytic enzymes
EP0954572A1 (en) 1997-01-10 1999-11-10 Novo Nordisk A/S Enzyme coupled with polymeric molecules for skin care
WO1998035026A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
CA2294567A1 (en) 1997-06-25 1999-01-07 Novo Nordisk A/S A modified polypeptide
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
CA2346929A1 (en) 1998-10-13 2000-04-20 Novozymes A/S A modified polypeptide with reduced immune response
DE69916306T2 (de) 1998-10-30 2005-05-04 Novozymes A/S Niedrigallergene proteinvarianten
WO2000026354A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
DK1131416T3 (da) 1998-11-27 2009-10-26 Novozymes As Lipolytiske enzymvarianter
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
HK1044477B (zh) 1999-03-17 2006-02-03 Abbott Laboratories Gmbh 治疗糖尿病的药物
WO2000060063A1 (en) * 1999-03-31 2000-10-12 Novozymes A/S Lipase variant
CA2366843A1 (en) * 1999-03-31 2000-10-12 Jesper Vind Lipase variant
AU781415B2 (en) 2000-02-08 2005-05-19 Dsm Ip Assets B.V. Use of acid-stable proteases in animal feed
AU2001254620A1 (en) * 2000-04-28 2001-11-12 Novozymes A/S Lipolytic enzyme variant
EP1352057B1 (en) * 2001-01-10 2009-03-25 Novozymes A/S Lipolytic enzyme variant
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
DE60233782D1 (de) 2001-02-07 2009-11-05 Novozymes As Lipasevarianten
DK2295556T3 (en) 2002-01-16 2015-01-26 Novozymes As Lipolytic Enzyme Variants and Method of Preparation thereof.
EP1592711A1 (en) 2003-02-06 2005-11-09 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
CA2523400C (en) * 2003-05-09 2015-03-17 Novozymes A/S Variant lipolytic enzymes
EP1639107B1 (en) 2003-06-19 2013-08-14 Novozymes A/S Improved proteases and methods for producing them
WO2004111216A2 (en) * 2003-06-19 2004-12-23 Novozymes A/S Phospholipase variants
AU2005206251A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
JP5032300B2 (ja) 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
HUE031245T2 (en) 2004-10-14 2017-06-28 Lilly Co Eli Preparations containing lipase, protease and amylase for the treatment of pancreatic insufficiency
EP1851311A2 (en) 2005-02-10 2007-11-07 Novozymes A/S Enzymatic enantioselective ester or amide hydrolysis or synthesis
EP1896057A2 (en) 2005-06-24 2008-03-12 Novozymes A/S Amylases for pharmaceutical use
CA2612648A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
JP2008546395A (ja) 2005-06-24 2008-12-25 ノボザイムス アクティーゼルスカブ 医薬使用のためのプロテアーゼ
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
DK1979477T3 (en) * 2006-01-23 2017-06-26 Novozymes As lipase variants
JP2009523900A (ja) * 2006-01-23 2009-06-25 ザ プロクター アンド ギャンブル カンパニー リパーゼと漂白剤触媒を含む組成物
JP5406040B2 (ja) * 2006-12-21 2014-02-05 ノボザイムス アクティーゼルスカブ 医薬使用のためのリパーゼ変異体

Also Published As

Publication number Publication date
AU2007337150A1 (en) 2008-07-03
NO20092729L (no) 2009-09-18
KR20090101930A (ko) 2009-09-29
CN101743308B (zh) 2015-09-16
AR064494A1 (es) 2009-04-08
JP2010512795A (ja) 2010-04-30
US9539311B2 (en) 2017-01-10
CN105112386A (zh) 2015-12-02
US20100034797A1 (en) 2010-02-11
CA3081308A1 (en) 2008-07-03
EP2455462A2 (en) 2012-05-23
TW200829698A (en) 2008-07-16
EP2261328A1 (en) 2010-12-15
CA2961041C (en) 2020-07-14
MX2009006597A (es) 2009-07-02
US8273348B2 (en) 2012-09-25
CA3081308C (en) 2024-02-20
EP2455460A2 (en) 2012-05-23
EP2261328B1 (en) 2013-11-20
EP2455461B1 (en) 2016-03-16
IL198893A0 (en) 2010-02-17
CA2670643A1 (en) 2008-07-03
US20120308543A1 (en) 2012-12-06
RU2009128067A (ru) 2011-01-27
BRPI0721103A2 (pt) 2014-03-04
EP2455461A3 (en) 2013-05-29
CA2670643C (en) 2017-04-25
CN101743308A (zh) 2010-06-16
EP2455459A2 (en) 2012-05-23
EP2455459A3 (en) 2013-04-24
EP2455462B1 (en) 2016-03-16
EP2099907A2 (en) 2009-09-16
US9029115B2 (en) 2015-05-12
EP2455459B1 (en) 2016-03-16
CA2961041A1 (en) 2008-07-03
WO2008079685A2 (en) 2008-07-03
EP2455461A2 (en) 2012-05-23
EP2455460A3 (en) 2012-12-26
EP2455462A3 (en) 2013-05-29
ZA200903598B (en) 2010-04-28
US20150209414A1 (en) 2015-07-30
WO2008079685A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
JP5406040B2 (ja) 医薬使用のためのリパーゼ変異体
US20090047266A1 (en) Lipases for Pharmaceutical Use
JP2008546396A (ja) 薬学的に使用するためのアミラーゼ
US8455235B2 (en) Protease variants for pharmaceutical use
AU2013203500B2 (en) Lipase variants for pharmaceutical use
AU2013200626B2 (en) Lipase variants for pharmaceutical use
HK1141553A (en) Lipase variants for pharmaceutical use
HK1113174A (en) Lipases for pharmaceutical use
HK1145697A (en) Protease variants for pharmaceutical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131031

R150 Certificate of patent or registration of utility model

Ref document number: 5406040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250